59 results
424B5
NBSE
NeuBase Therapeutics Inc
30 Jun 23
Prospectus supplement for primary offering
8:42am
of our employees.
In addition, competitors and others are likely in the future to attempt to recruit our employees. The loss of the services of any … that may be approved for the indications we are investigating. In addition, the COVID-19 pandemic may negatively impact our ability to recruit
8-K
EX-99.2
NBSE
NeuBase Therapeutics Inc
22 May 23
Regulation FD Disclosure
7:00am
and recruit the cell’s own machinery to repair the mutation. This high-fidelity non-immunogenic approach is expected to offer advantages compared
8-K
EX-99.1
NBSE
NeuBase Therapeutics Inc
11 May 23
NeuBase Reports Business Update and Financial Results for the First Quarter of 2023
4:20pm
compound and recruit the cell’s own machinery to repair the mutation. This is the approach behind our in vivo gene editing platform,” stated Dietrich
424B5
NBSE
NeuBase Therapeutics Inc
29 Dec 22
Prospectus supplement for primary offering
5:03pm
to attempt to recruit our employees. The loss of the services of any of our key personnel, the inability to attract or retain highly qualified … , the COVID-19 pandemic may negatively impact our ability to recruit and enroll patients for our clinical trials because they may be reluctant or unable
8-K
EX-99.1
NBSE
NeuBase Therapeutics Inc
21 Dec 22
NeuBase Therapeutics Reports Business Update and Financial Results
8:10am
, without the requirement for a flanking protospacer adjacent motif (PAM) sequence, and recruit the cell’s own DNA repair machinery to correct transition
424B5
c3t8vq5j
27 Aug 21
Prospectus supplement for primary offering
5:21pm
424B5
0tqw 137j8k
23 Apr 21
Prospectus supplement for primary offering
4:05pm
424B5
sy8w8k
21 Apr 21
Prospectus supplement for primary offering
4:03pm
424B3
ydwu2c0x wju
6 Jun 19
Prospectus supplement
5:15pm